When Was Retatrutide Invented?

Retatrutide was invented in the late 2010s by scientists at Eli Lilly and Company, who engineered a single molecule that activates three receptors at once: GIP, GLP-1, and glucagon. The compound is known internally as LY3437943, and the discovery work behind it was published in Cell Metabolism in 2022. There is no single public invention date, because the molecule existed in a Lilly laboratory and in patent filings years before it appeared in any journal.

So if you are asking when was retatrutide created, the accurate answer is a range rather than a date: design and synthesis in the late 2010s, public disclosure between roughly 2018 and 2022, and the first dosing in humans around 2020.

Who Invented Retatrutide?

Retatrutide was invented by researchers at Eli Lilly and Company in Indianapolis, Indiana. A Lilly discovery team that also worked on tirzepatide designed the peptide and characterized it in preclinical models before it ever reached a clinic.

• Company: Eli Lilly and Company
• Internal code: LY3437943
• Drug class: triple agonist of the GIP, GLP-1, and glucagon receptors
• Format: peptide engineered for once-weekly injection

The same research group developed tirzepatide, a dual GIP and GLP-1 agonist, several years earlier. Retatrutide was the next step: adding a third receptor target to test whether broader metabolic signaling produced greater weight loss.

Retatrutide Timeline: From Lab Notebook to Clinical Trials

Because retatrutide moved from chemistry bench to human studies over roughly five years, the development story is easier to follow in a table.

Year	Milestone	Why it matters
Late 2010s	Lilly researchers design and synthesize LY3437943	The molecule is created, but not yet public
Around 2018 to 2019	Patent applications describe the triple agonist	The closest thing to a legal record of invention
Around 2020	First Phase 1 human trials begin	First dosing in people
2022	Preclinical discovery paper in Cell Metabolism	The science becomes public
2023	Phase 2 obesity results in the New England Journal of Medicine and Phase 1b type 2 diabetes results in The Lancet	Largest early readouts, and the start of heavy public interest
2023 to present	Phase 3 TRIUMPH program	Still an investigational drug

One number explains the sudden attention in 2023. In the Phase 2 obesity trial, participants taking 12 mg weekly lost an average of about 24% of their body weight at 48 weeks. Those results arrived roughly five years after the molecule itself was invented.

Why There Is No Official Invention Date

Drug discovery does not come with a timestamp. A candidate molecule is typically designed, redesigned, synthesized, and tested dozens of times before anyone calls it a lead compound.

1. Design and synthesis: chemists build the peptide and test it in cells and animals.
2. Patent filing: the company files a patent, which is the nearest thing to a legal invention date.
3. Patent publication: the application becomes public about 18 months after filing.
4. Peer-reviewed publication: preclinical and clinical data appear in journals years after the work started.
5. Regulatory approval: the public often treats approval as the real date, even though the invention happened a decade earlier.

For retatrutide, the patent literature and the 2022 Cell Metabolism paper both point to the late 2010s as the creation window. Eli Lilly has never issued a press release announcing a specific invention date.

How Retatrutide Compares With Other Incretin Drugs

Retatrutide arrived on the scene later than the two best-known incretin drugs, and that timing shows in its design.

Drug	Receptor targets	Developed by	First human trials
Semaglutide	GLP-1	Novo Nordisk	Early 2010s
Tirzepatide	GIP and GLP-1	Eli Lilly	Mid-2010s
Retatrutide	GIP, GLP-1, and glucagon	Eli Lilly	Around 2020

Each new molecule added a receptor target, and each one was invented several years before the general public heard about it.

Where Retatrutide Stands Today

Retatrutide is not FDA-approved for human use in the United States. It remains an investigational drug, and Eli Lilly has not announced a firm approval date.

Phase 3 timing

The Phase 3 TRIUMPH program launched in 2023 and includes trials in obesity, type 2 diabetes, obstructive sleep apnea, and knee osteoarthritis. That is why so many people ask when will retatrutide be available; the realistic answer is that approval is unlikely before the late 2020s, and only if the Phase 3 data hold up.

Researchers also compare it with older fat-loss peptides. Searchers frequently look at aod 9604 vs retatrutide, even though the two are very different molecules: AOD-9604 is a fragment of human growth hormone studied for fat metabolism, while retatrutide is a triple-receptor agonist.

Research Chemicals, Dosing Questions, and Safety

Retatrutide appears on gray-market research chemical websites even though it has no approved human use. These products are not made under pharmaceutical manufacturing standards, and independent testing has repeatedly found purity and identity problems in the peptide market.

That market also generates questions that have nothing to do with the laboratory. People who research aod 9604 and retatrutide side by side often ask how long does retatrutide last after adding bac water, a question that only applies to reconstituted vials sold for research use.

Timing and stacking questions, such as when to take aod 9604 peptide, show up in the same forums. None of that information substitutes for medical care, and none of it makes an unapproved peptide safe to inject.

In the clinical trials, the most common side effects were nausea, diarrhea, vomiting, and constipation, and they were more frequent at higher doses. Anyone considering any weight-loss drug should discuss the risks with a licensed healthcare professional, especially if they take other medications or have a history of gallbladder, pancreas, or thyroid problems.

COMMON QUESTIONS

Frequently Asked Questions

When was retatrutide invented?

Retatrutide was designed and synthesized by Eli Lilly scientists in the late 2010s. Patent filings and a 2022 discovery paper in Cell Metabolism are the clearest public records of that work, and the first human trials began around 2020.

Is retatrutide FDA-approved?

No. Retatrutide is not FDA-approved for human use in the United States. It is still an investigational drug in Phase 3 trials, and approval is unlikely before the late 2020s, if it happens at all.

Who invented retatrutide?

It was invented by researchers at Eli Lilly and Company, the same company that developed tirzepatide. The compound's internal code is LY3437943, and it works as a triple agonist at the GIP, GLP-1, and glucagon receptors.